The mature 12-month data and strong financing remove key near-term funding and regulatory uncertainty. Watch for ASCO presentation (May 29-June 2) and confirmatory study initiation in Q4 2026 as the next catalysts. The stock's $12M market cap suggests significant upside if accelerated approval is granted, but binary regulatory risk remains.
Price Chart
Executive Summary
Cellectar Biosciences announced updated 12-month follow-up data from its Phase 2b CLOVER WaM trial of iopofosine I 131 in Waldenström macroglobulinemia, showing 83.6% ORR and 61.8% MRR with median DoR of 17.8 months. The FDA-requested dataset strengthens the case for accelerated approval, and the company plans to initiate a confirmatory study in Q4 2026, supported by a recently announced oversubscribed financing of up to $140M.
Key Financial Metrics
Key Facts
- 83.6% overall response rate (ORR) and 61.8% major response rate (MRR) in 55-patient per-protocol population
- Median duration of response (DoR) of 17.8 months and median progression-free survival (PFS) of 13.5 months
- In BTKi-exposed patients (n=39): MRR 64.1%, median DoR 18.2 months, median PFS 15.9 months
- In BTKi-refractory patients (n=33): MRR 63.6%, median DoR 18.2 months, median PFS 14.8 months
- FDA-requested ≥12-month follow-up completed on all patients, meeting key regulatory expectation for accelerated approval
- Company plans to initiate confirmatory randomized study in Q4 2026 with PFS as primary endpoint
- Recently announced oversubscribed financing of up to $140M with healthcare institutional investors supports confirmatory study and NDA filing
- No significant bleeding events and low infection rates (<10%) reported; safety profile manageable
- Data accepted for presentation at ASCO 2026 (May 29-June 2)
Financial Impact
Up to $140M in new financing announced; total addressable market for third-line+ WM therapy estimated at ~5,700 patients with no FDA-approved BTKi post-progression options
Risk Factors
- Accelerated approval not guaranteed; FDA may require additional data or reject submission
- Confirmatory study may fail to meet PFS endpoint, risking withdrawal of any accelerated approval
- Heavily pretreated population (median 4 prior lines) may limit commercial adoption if real-world outcomes differ
- Dilution risk from up to $140M financing; exact terms not yet disclosed
- Small market cap ($12M) amplifies volatility on any news
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287522 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $1.19 | awaiting T+60 | — | $1.22 (+2.52%) |
Aug 13, 2026 10w ago | 8-K | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Aug 13, 2026 10w ago | Press Release | $2.48 | awaiting T+60 | — | $1.22 (−50.81%) |
Jun 1, 2026 21w ago | Press Release | $2.97 $2.54 | ▼ −14.48% | ▼ −15.71% | $1.22 (−58.92%) |
May 29, 2026 21w ago | S-1/A | $3.14 $2.52 | ▲ +19.75% | ▲ +20.93% | $1.22 (+61.15%) |
May 28, 2026 21w ago | DEFA14A | $3.14 $2.52 | ▼ −19.75% | ▼ −20.93% | $1.22 (−61.15%) |
May 19, 2026 22w ago | S-1 | $3.17 $2.60 | ▲ +17.98% | ▲ +22.98% | $1.22 (+61.51%) |
May 14, 2026 23w ago | 8-K | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 14, 2026 23w ago | Press Release | $3.20 $2.60 | ▼ −18.75% | ▼ −22.34% | $1.22 (−61.87%) |
May 11, 2026 24w ago | Press Release | $3.06 $2.52 | ▼ −17.65% | ▼ −22.04% | $1.22 (−60.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers